Publications by authors named "Peter Beitsch"

Claim this Profile
U
Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes.
Sarah M Nielsen, Emily M Russell, Rachel E Ellsworth, Kevin S Hughes, Brandie Heald, Peter D Beitsch

J Natl Compr Canc Netw· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine-Biology Is Still King.
Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth

Int J Mol Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
Alejandro Ríos-Hoyo, Erin Cobain, Laura A Huppert, Peter D Beitsch, Thomas A Buchholz

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives.
Brandie Heald, Sara Pirzadeh-Miller, Rachel E Ellsworth, Sarah M Nielsen, Emily M Russell, Peter Beitsch

J Natl Cancer Inst· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
James V Pellicane, Peter D Beitsch, David T Rock, Raye J Budway, Carrie L Dul

Surg Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

JAMA Surg· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Pat W Whitworth, Peter D Beitsch, Mary K Murray, Paul D Richards, Angela Mislowsky

JCO Precis Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
Pat W Whitworth, Peter D Beitsch, Rakesh Patel, Barry Rosen, Gia Compagnoni

JAMA Netw Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial.
E Shelley Hwang, Peter Beitsch, Peter Blumencranz, David Carr, Anees Chagpar

JAMA Surg· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Pat Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee

Ann Surg Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Pat W Whitworth, Peter D Beitsch, James V Pellicane, Paul L Baron, Laura A Lee

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Eric D Whitman, Vadim P Koshenkov, Brian R Gastman, Deri Lewis, Eddy C Hsueh, Peter D Beitsch

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L Slingluff, Karl D Lewis, Robert Andtbacka, John Hyngstrom, Mohammed Milhem, Peter Beitsch

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial.
John F Thompson, Lauren E Haydu, Roger F Uren, Robert H Andtbacka, Jonathan S Zager, Peter D Beitsch

Ann Surg· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.
Michael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, Alastair M Thompson, Richard J Bold, Peter D Beitsch

Ann Surg Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium".
Peter Beitsch, Pat Whitworth, Rakesh Patel

Breast Cancer Res Treat· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.
Michael D Alvarado, Elizabeth A Mittendorf, Mediget Teshome, Alastair M Thompson, Richard J Bold, Peter D Beitsch

Ann Surg Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M.S. Copur et al, A. Taylor et al, and P.S. Rajagopal et al.
Peter Beitsch, Kevin Hughes, Pat Whitworth

J Clin Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, Jinil Han, Jeong Eon Lee, Jong Won Lee, Peter D Beitsch

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.
Floris H Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch

NPJ Breast Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines Do Not Proscribe Surgeons Performing Genetic Testing.
Kevin S Hughes, Peter Beitsch, Steven Chen

JAMA Surg· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Peter D Beitsch, Pat W Whitworth, Kevin Hughes, Rakesh Patel, Barry Rosen

J Clin Oncol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence based outcomes of the American Society of Breast Surgeons Nipple Sparing Mastectomy Registry.
Sunny D Mitchell, Shawna C Willey, Peter Beitsch, Sheldon Feldman

Gland Surg· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Armando E Giuliano, Karla V Ballman, Linda McCall, Peter D Beitsch, Meghan B Brennan

JAMA· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Mark B Faries, John F Thompson, Alistair J Cochran, Robert H Andtbacka, Nicola Mozzillo, Peter D Beitsch

N Engl J Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis